2. NF-κB Metabolic Enzyme/Protease Apoptosis
  3. Keap1-Nrf2 Glutathione Peroxidase Ferroptosis
  4. Gingerenone A

Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice.

For research use only. We do not sell to patients.

CAS No. : 128700-97-0

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Gingerenone A:

Gingerenone A Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
ELISA
IF
Cell Migration/Invasion Assay
WB
Histological Imaging/Staining

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    The vitality of MLE-12 cells following 24 h of treatment with varying concentrations of Gingerenone A (GA) (5-80 μM). The results indicated that GA concentrations below 40 μM had no cytotoxic effects on MLE-12 cells.

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    Gingerenone A (GA) (5-80 μM) treatment significantly decreased the HDM-induced secretion of IL-25 and IL-1β by epithelial cells.

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    Representative immunofluorescence images showing p65 nuclear translocation in MLE-12 cells after treatment with different concentrations of HDM and/or Gingerenone A (GA) (5-20 μM) (scale bar = 50 μm), along with quantitative analysis of the nuclear/cytoplasmic fluorescence intensity ratio. The results showed that GA treatment reduced HDM-induced NF-κB nuclear translocation. Quantitative analysis of nuclear/cytoplasmic fluorescence intensity ratios reveals significantly lower NF-κB nuclear accumulation in the GA group (10-20 μM) versus the HDM group (P < 0.05).

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    Representative images (scale bar = 100 μm) of the migration assay of MLE-12 cells under Gingerenone A (GA) and HDM stimulation, along with the migration cell ratio relative to the control group (n = 3). The results showed that 48-h of HDM stimulation increased MLE-12 cell migration. However, after GA treatment at 5, 10, and 20 μM, migration rates significantly decreased. These data indicate that GA substantially inhibits HDM-induced increases in airway epithelial cell migration.

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    Western blot analysis for E-cadherin, N-cadherin and vimentin in MLE-12 cells under Gingerenone A (GA) (5-20 μM) and HDM stimulation (n = 3). The results revealed that treatment with HDM caused a significant reduction in E-cadherin (epithelial marker) and simultaneous elevation of N-cadherin and vimentin (mesenchymal markers). In contrast, GA treatment effectively counteracted these changes in protein levels.

    Gingerenone A purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Sep 30:120656.  [Abstract]

    Gingerenone A (GA) (10-20 mg/kg; i.p.; once daily for 7 days) markedly alleviated extensive inflammatory cell infiltration in the pulmonary vasculature and alveoli of asthmatic mice.

    View All Glutathione Peroxidase Isoform Specific Products:

    View All Isoforms
    GPX1 GPX4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice[1][2][3][4].

    IC50 & Target

    GPX4

     

    Cellular Effect
    Cell Line Type Value Description References
    HEK293 EC50
    24 μM
    Compound: 40
    Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay
    Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay
    		[PMID: 20004045]
    In Vitro

    Gingerenone A (2.5-40 μM, 5 h) overcomes insulin resistance and increases glucose uptake in 3T3-L1 cells by inhibiting S6K1 activity[1].
    Gingerenone A (40 μM, 6 days) inhibits lipogenesis and lipid accumulation in 3T3-L1 cells[2].
    Gingerenone A (0-40 μM, 6 days) suppresses the proliferation and hypertrophy of 3T3-L1 cells, regulating the expression or phosphorylation levels of proteins related to lipogenesis and fatty acid metabolism[2].
    Gingerenone A promotes anti-proliferation and senescence in breast cancer cells induced by oxidative stress[3].
    Gingerenone A with an IC50 values for breast cancer cells (SKBR3, MCF-7 and MDA-MB-231) is 50.41, 42.67, 56.29 µM in a 48-hour TP experiment [3].
    Gingerenone A (80 μM, 48 h) causes a delay in the G2/M phase of MCF7 and MDA-MB-231 cells[3].
    Gingerenone A (80 μM, 1.5-3 h) induces an increase in ROS levels in MCF7 and MDA-MB-231 cells[3].
    Gingerenone A (0-80 μM, 48 h) induces senescence in MCF7 and MDA-MB-231 cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Gingerenone A Related Antibodies

    Western Blot Analysis[1]

    Cell Line: 3T3-L1
    Concentration: 0, 2.5, 5, 10, 20, 40 μM
    Incubation Time: 5 h
    Result: Increased AKTS473 and S6K1T389, decreased phosphorylation of S6S235/236 and insulin receptor substrate 1 (IRS-1) S1101, and increased binding of IRS-1 to PI3K.

    Immunofluorescence[2]

    Cell Line: 3T3-L1
    Concentration: 40 μM
    Incubation Time: 6 days
    Result: Inhibits cellular adipogenesis and lipid accumulation.

    Western Blot Analysis[2]

    Cell Line: 3T3-L1
    Concentration: 0, 10, 20, 40 μM
    Incubation Time: 6 days
    Result: Inhibited PPAR-γ, C/EBP-α, and FAS protein levels, decreased SREBP-1 and FAS (lipogenesis markers) protein expression levels, and increased PGC-1α and CPT-1 (fatty acid oxidation markers) protein expression levels.

    Cell Viability Assay[3]

    Cell Line: MCF7, SKBR3, M10, MDA-MB-231
    Concentration: 0, 20, 40, 60, 80μM
    Incubation Time: 48 h
    Result: Inhibited tumor cell proliferation with little effect on normal cells.

    Cell Cycle Analysis[3]

    Cell Line: MCF7, MDA-MB-231
    Concentration: 80 μM
    Incubation Time: 48 h
    Result: Increased subG1, moderately decreased G1, and increased G2/M populations.

    Real Time qPCR[3]

    Cell Line: MCF-7, MDA-MB-231
    Concentration: 0, 40, 80 μM
    Incubation Time: 5 h
    Result: Upregulated the expression of aging-related genes EDN1, ANKRD1, CDKN1A, SERPINE and TAGLN.
    In Vivo

    Gingerenone A (10-50 mg/kg, orally, once a day, 15 weeks) reduces the increase in fat mass induced by a high-fat diet in mice by decreasing the size of fat cells, thereby inhibiting obesity and inflammation in adipose tissue[2].
    Gingerenone A (5-20 mg/kg, orally, once a day, 7 days) can alleviate ferroptosis in the SLI of DSS-induced colitis mice, and its protective effect is associated with the activation of the Nrf2-Gpx4 signaling pathway[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: HFD mice[2]
    Dosage: 10, 50 mg/kg; daily; 15 weeks
    Administration: Oral
    Result: Reduced fat gain without significantly affecting caloric intake, reduced visceral fat mass, and made fat cells smaller.
    Animal Model: Mice induced by DSS[6]
    Dosage: 5, 20 mg/kg; daily; 7 days
    Administration: Oral
    Result: Alleviated DSS-induced liver pathological damage, liver parameters and cytokine levels, increased antioxidant enzyme activities, alleviated ferroptosis, upregulated GPX4 expression, and activated Nrf2.
    Molecular Weight

    356.41

    Formula

    C21H24O5
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(/C=C/CCC1=CC=C(O)C(OC)=C1)CCC2=CC=C(O)C(OC)=C2
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (280.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.8058 mL 14.0288 mL 28.0576 mL
    5 mM 0.5612 mL 2.8058 mL 5.6115 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (7.01 mM); Clear solution; Need ultrasonic

      This protocol yields a clear solution of 2.5 mg/mL.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (7.01 mM); Clear solution; Need ultrasonic

      This protocol yields a clear solution of 2.5 mg/mL.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.95%

    SDS (537 KB)

    COA (243 KB) HNMR (135 KB) RP-HPLC (194 KB) LCMS (111 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.8058 mL 14.0288 mL 28.0576 mL 70.1439 mL
    5 mM 0.5612 mL 2.8058 mL 5.6115 mL 14.0288 mL
    10 mM 0.2806 mL 1.4029 mL 2.8058 mL 7.0144 mL
    15 mM 0.1871 mL 0.9353 mL 1.8705 mL 4.6763 mL
    20 mM 0.1403 mL 0.7014 mL 1.4029 mL 3.5072 mL
    25 mM 0.1122 mL 0.5612 mL 1.1223 mL 2.8058 mL
    30 mM 0.0935 mL 0.4676 mL 0.9353 mL 2.3381 mL
    40 mM 0.0701 mL 0.3507 mL 0.7014 mL 1.7536 mL
    50 mM 0.0561 mL 0.2806 mL 0.5612 mL 1.4029 mL
    60 mM 0.0468 mL 0.2338 mL 0.4676 mL 1.1691 mL
    80 mM 0.0351 mL 0.1754 mL 0.3507 mL 0.8768 mL
    100 mM 0.0281 mL 0.1403 mL 0.2806 mL 0.7014 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Gingerenone A Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Gingerenone A128700-97-0Keap1-Nrf2Glutathione PeroxidaseFerroptosisAnti-inflammatoryanti-diabeticanti-tumorpro-agingInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Gingerenone A
    Cat. No.:
    HY-120912
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (537 KB) Français - FR (537 KB) Deutsch - DE (537 KB) Norwegian - NO (537 KB) Español - ES (537 KB) Swedish - SV (537 KB) Italian - IT (537 KB) Korean - KR (537 KB) Portuguese - PT (537 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.